What Happens After a PRAC Recommendation? CHMP, CMDh and the European Commission

Introduction

A PRAC recommendation is an important regulatory milestone, but it is not automatically the final legal outcome of a pharmacovigilance referral.

This distinction is fundamental to understanding the EU medicines regulatory system.

PRAC performs the pharmacovigilance assessment and adopts a recommendation within the scope of the applicable referral procedure. What happens next depends principally on the legal basis of the referral and the marketing-authorisation status of the products concerned.

For centrally authorised medicines, the subsequent pathway generally involves the Committee for Medicinal Products for Human Use (CHMP). For certain referrals concerning nationally authorised medicines, the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has a corresponding role. Where the applicable legislation requires a Union decision, the process then moves to the European Commission, which adopts the legally binding decision through the applicable decision-making procedure.

These stages should not be collapsed into the phrase “EMA decided”. EMA is the regulatory agency coordinating important parts of the process, but PRAC, CHMP, CMDh and the European Commission perform different functions.

The distinction is particularly important for a QPPV or regulatory professional because a referral can generate several different documents, each with a different legal or scientific status:

• PRAC recommendation;
• CHMP opinion;
• CMDh position or agreement, depending on the procedure;
• European Commission decision;
• revised product information;
• implementation documentation; and
• national regulatory actions for nationally authorised medicines.

A correct reading of the sequence is therefore:

PRAC scientific assessment
        ↓
PRAC recommendation
        ↓
Applicable subsequent committee pathway
        ↓
CHMP opinion / CMDh position or agreement
        ↓
European Commission decision where required
        ↓
Implementation in the affected marketing authorisations
        ↓
Updated product information and ongoing pharmacovigilance

The exact route depends on the legal procedure. This article explains the general architecture and then distinguishes the principal pathways.

1. A PRAC Recommendation Is Not the Same as a Final Legal Decision

The first concept to establish is the difference between scientific assessment, committee recommendation or opinion, and legally operative regulatory decision.

PRAC's role is centred on pharmacovigilance and risk assessment. In a pharmacovigilance referral, it evaluates the safety concern and adopts a recommendation.

For an Article 20 pharmacovigilance procedure, EMA states that the PRAC recommendation is sent to CHMP for adoption of an opinion. For an Article 31 pharmacovigilance referral, the subsequent pathway depends on whether centrally authorised medicines are included and on the products within scope. citeturn0search0turn0search4

This creates three conceptually different stages:

The terminology matters.

A recommendation is not automatically a decision.

An opinion is not necessarily the same thing as the final legally binding act.

A CMDh position has a different legal function from a Commission decision.

The implementation obligations for a centrally authorised product also differ from those for a nationally authorised product.

2. Why the Product's Authorisation Status Matters

The next step after PRAC depends heavily on the authorisation route of the affected medicines.

The most useful first distinction is between:

• centrally authorised products (CAPs); and
• nationally authorised products (NAPs).

NAPs can include medicines authorised through:

• purely national procedures;
• the mutual recognition procedure (MRP); or
• the decentralised procedure (DCP).

A referral may contain several products, and those products do not necessarily share the same authorisation route.

This is why the question “What happens after PRAC?” cannot be answered without first asking:

Which products are covered by the referral, and how are those products authorised?

For an Article 20 pharmacovigilance procedure, the products are centrally authorised, so the subsequent committee pathway is CHMP.

For an Article 31 pharmacovigilance referral, the pathway can differ. EMA explains that where centrally authorised products are included, the PRAC recommendation is followed by a CHMP opinion; where the referral concerns only nationally authorised products, the subsequent process involves CMDh. citeturn0search4

The authorisation route therefore determines the institutional pathway after the common pharmacovigilance assessment.

3. Article 20 Pharmacovigilance: PRAC to CHMP

An Article 20 pharmacovigilance procedure concerns centrally authorised medicinal products.

EMA's current Article 20 pharmacovigilance Q&A states that, after PRAC adopts its recommendation, the recommendation is sent to CHMP for adoption of an opinion. CHMP considers the PRAC recommendation and assessment report at its plenary meeting and normally aims to adopt its opinion at the following plenary meeting, subject to the applicable procedure and timetable. citeturn0search0

The simplified pathway is:

European Commission initiates Article 20 PhV procedure
                 ↓
                PRAC
                 ↓
        PRAC recommendation
                 ↓
                CHMP
                 ↓
          CHMP opinion
                 ↓
     European Commission decision
                 ↓
       CAP implementation

The CHMP stage is not merely administrative transmission.

CHMP considers the PRAC recommendation and assessment report within its own remit. EMA's Article 20 Q&A states that CHMP adopts an opinion on maintenance, variation, suspension or revocation of the marketing authorisations concerned and that the CHMP opinion can differ from the PRAC recommendation, in which case the scientific grounds for the difference are explained. citeturn0search0

This is a critical principle:

PRAC's recommendation is highly important, but the subsequent committee has its own legal and scientific role.

4. What CHMP Actually Considers

CHMP does not normally restart the entire pharmacovigilance assessment from zero.

The PRAC recommendation and assessment report provide the central pharmacovigilance analysis. CHMP considers that material within the framework of the centralised marketing authorisation system.

The CHMP assessment may therefore focus on questions such as:

• whether the PRAC recommendation is supported by the scientific evidence;
• whether the recommended action is appropriate for the centrally authorised products;
• whether the proposed regulatory measures are consistent with the applicable legal framework;
• whether the proposed product-information changes are appropriate; and
• whether any additional scientific issue needs to be resolved before the opinion is adopted.

EMA's Article 20 Q&A states that CHMP adopts its opinion by consensus or by majority vote. It also provides for an oral explanation in exceptional circumstances and requires scientific explanation where the CHMP opinion differs from the PRAC recommendation. citeturn0search0

The important conceptual point is that CHMP endorsement is a committee-level scientific and regulatory step within the centralised procedure, not simply a clerical confirmation of PRAC wording.

5. What If CHMP Agrees With PRAC?

In the common situation where CHMP agrees with the PRAC recommendation, the CHMP opinion reflects the conclusion supported by the PRAC assessment.

The resulting documentation can incorporate:

• the PRAC recommendation and assessment report;
• the scientific grounds for the CHMP opinion;
• the products concerned;
• revised product information where applicable; and
• other regulatory measures relevant to the outcome.

The fact that CHMP agrees with PRAC does not eliminate the distinction between the two stages.

PRAC remains the pharmacovigilance committee that performed the safety assessment and adopted its recommendation. CHMP remains the committee that adopts the opinion applicable within the centralised marketing-authorisation framework.

This distinction becomes particularly useful when reading historical referral documentation. A reader should be able to determine which conclusions originated from PRAC and which represent the final CHMP position.

6. What If CHMP Differs From PRAC?

The possibility of disagreement is an important safeguard in the EU regulatory system.

EMA's Article 20 guidance explicitly states that where the CHMP opinion differs from the PRAC recommendation, CHMP attaches an explanation of the scientific grounds for the difference. citeturn0search0

The difference should therefore not be interpreted as a procedural failure.

It demonstrates that the committees have distinct legal responsibilities and that the evidence can be considered from the perspective required by the relevant regulatory framework.

For a regulatory professional, this means that a complete review of a referral should not stop at the PRAC recommendation.

If the subsequent CHMP opinion differs materially, the reason for the difference becomes part of the regulatory history of the product.

7. Article 31 Pharmacovigilance Referrals: Two Principal Pathways

Article 31 pharmacovigilance referrals require more careful analysis because the procedure can involve both centrally and nationally authorised medicines.

The key branching point is whether centrally authorised products are included.

Where centrally authorised products are included

The PRAC recommendation proceeds to CHMP for an opinion.

The simplified pathway is:

Article 31 referral
      ↓
     PRAC
      ↓
PRAC recommendation
      ↓
     CHMP
      ↓
 CHMP opinion
      ↓
European Commission decision, where required

Where only nationally authorised products are included

The subsequent pathway involves CMDh.

Conceptually:

Article 31 referral
      ↓
     PRAC
      ↓
PRAC recommendation
      ↓
    CMDh
      ↓
CMDh position / applicable agreement
      ↓
Implementation in Member States

The exact legal consequences and implementation mechanism depend on the applicable provisions of Directive 2001/83/EC and the type of authorisation concerned.

EMA's Article 31 pharmacovigilance guidance specifically distinguishes these pathways. citeturn0search4

8. Why CMDh Is Different From CHMP

CMDh is not simply a smaller version of CHMP.

Its role is connected to nationally authorised medicines, particularly the coordination of Member States in relation to the mutual recognition and decentralised procedures and related regulatory processes.

This reflects a fundamental feature of the EU medicines system:

The Union has both centrally authorised medicines and nationally authorised medicines operating within a common EU legal framework.

For a nationally authorised product, the final regulatory effect is not necessarily created by a centralised marketing authorisation decision equivalent to that for a CAP.

Instead, the Member States implement the agreed Union outcome through their national marketing authorisations, using the applicable procedure.

This is why the post-PRAC pathway must be understood in relation to the authorisation route.

9. CMDh's Role After a PRAC Recommendation

Where a pharmacovigilance referral concerns only nationally authorised medicines, CMDh considers the PRAC recommendation within the applicable legal framework.

The purpose is to achieve a coordinated position among Member States so that the affected national marketing authorisations are maintained or varied consistently with the Union assessment.

The result is therefore not best described as “CMDh grants a new EU marketing authorisation”. It does not.

Rather, CMDh provides the coordination mechanism through which the outcome is applied to nationally authorised medicines.

EMA's current information on PRAC safety-signal recommendations illustrates the distinction: recommendations for regulatory action concerning CAPs are submitted to CHMP for endorsement, whereas recommendations concerning NAPs are sent to CMDh for information, with Member State regulatory authorities responsible for overseeing adherence. citeturn0search3

A formal referral can involve a more specific CMDh procedure than the routine signal-management pathway, but the underlying institutional distinction remains important.

10. The European Commission's Role

The European Commission occupies a different position from EMA committees.

In procedures where the legislation provides for a Commission decision, the Commission is the institution that adopts the legally binding Union decision following the applicable scientific procedure.

This is especially clear for centrally authorised medicines.

A simplified centralised sequence is:

PRAC recommendation
       ↓
CHMP opinion
       ↓
European Commission
       ↓
Binding Union decision

The Commission decision is therefore the point at which the regulatory conclusion becomes legally operative in the manner prescribed by the legislation.

For nationally authorised medicines, the Commission can also have a role in certain Union referral procedures where the applicable legislation requires a Commission decision. The legal effect and addressee of that decision differ from the CAP situation.

EMA's current referral guidance explains that, following a final CHMP opinion in an Article 31 procedure, the Commission starts the decision-making process leading to a binding decision addressed either to the MAHs/applicants for centrally authorised products or to Member States for nationally authorised products, depending on the products concerned. citeturn0search2

This distinction is essential when determining what the final regulatory instrument actually does.

11. Scientific Opinion Versus Binding Decision

The terminology can be confusing because the documents can look similar in practical regulatory use.

A CHMP opinion is the scientific committee's formal position within the applicable legal procedure.

A European Commission decision is the legally binding act where the legislation requires a Commission decision.

The distinction matters because an MAH should not assume that a committee opinion alone is the final implementation instruction for a CAP.

Similarly, for NAPs, the implementation route may involve national competent authorities and CMDh coordination rather than a centralised marketing authorisation decision.

For a QPPV, the practical question is therefore not simply:

“What did PRAC recommend?”

It is:

“What is the final legally operative outcome, and how does that outcome apply to each affected authorisation?”

12. Re-examination of a CHMP Opinion

A further safeguard exists before a CHMP opinion becomes final in the relevant procedures: the possibility of re-examination, where provided for by the applicable legislation.

EMA's current Article 31 material states that a concerned MAH/applicant may notify EMA within 15 calendar days of receipt of the CHMP opinion of its intention to request re-examination. The detailed grounds must then be submitted within 60 calendar days of receipt of the opinion. citeturn0search2

These are legal/procedural time limits, not general “response windows” that should be transferred to every referral.

During re-examination, CHMP considers the grounds submitted and adopts a final opinion within the applicable framework. Where no valid request is made within the prescribed period, the opinion becomes final according to the procedure.

For regulatory teams, this means that receipt of a CHMP opinion should trigger an immediate procedural assessment of whether a re-examination option exists and whether the MAH intends to exercise it.

The QPPV should be involved where the opinion concerns pharmacovigilance matters, particularly where the grounds for re-examination depend on safety evidence, risk characterisation or the adequacy of risk-management measures.

13. What Happens to the Product Information?

The regulatory conclusion is normally accompanied by the practical task of translating the scientific and regulatory outcome into authorised product information.

Depending on the outcome, this can involve changes to:

• the Summary of Product Characteristics (SmPC);
• labelling; and/or
• the package leaflet.

For centrally authorised products, the final Union decision and associated product-information changes are implemented within the centralised authorisation framework.

For nationally authorised products, the agreed outcome is implemented through the national marketing authorisations according to the applicable procedure.

The exact wording is important. A regulatory decision may specify precise wording, conditions or restrictions rather than simply stating that “the warning should be strengthened”.

This is why product-information implementation should be treated as a controlled regulatory activity rather than as ordinary editorial revision.

The detailed process for converting a referral outcome into revised product information is addressed separately in the later article on how an EMA referral changes the SmPC, Package Leaflet and Risk Management Plan.

14. The Referral Does Not End When the Decision Is Published

A final decision does not necessarily end the pharmacovigilance work.

The outcome may create continuing obligations, including:

• implementation of revised product information;
• additional risk-minimisation measures;
• additional pharmacovigilance activities;
• communication measures;
• post-authorisation safety studies or other commitments where applicable;
• monitoring of implementation; and
• continued evaluation of emerging evidence.

The regulatory outcome therefore becomes part of the medicine's ongoing pharmacovigilance and lifecycle-management framework.

A referral should be understood as a transition from one regulatory state to another, not simply as a document that is filed and forgotten.

15. A Practical Document Hierarchy

When reviewing a completed pharmacovigilance referral, a regulatory professional should distinguish the documents in the following conceptual order:

Referral notification
        ↓
Questions / timetable
        ↓
PRAC assessment report
        ↓
PRAC recommendation
        ↓
CHMP opinion OR CMDh outcome, as applicable
        ↓
European Commission decision, where required
        ↓
Final product information / implementation documents
        ↓
Ongoing pharmacovigilance obligations

The hierarchy is not merely chronological.

Each document answers a different question.

A reader who understands this hierarchy can reconstruct the regulatory history without confusing scientific reasoning with legal effect.

14. Implementing the Outcome for Centrally Authorised Medicines

Once the applicable Union decision is adopted, the MAH must translate the outcome into the authorised status of the centrally authorised product.

The implementation is not simply a matter of changing a document on the company's side. The regulatory outcome establishes what is authorised, restricted, suspended or otherwise required under the applicable decision.

Where product information is changed, the MAH must ensure that the approved wording is incorporated into the applicable product-information documents and that the resulting versions are controlled through the company's regulatory and quality systems.

The implementation may also require corresponding changes to other controlled materials or activities, depending on the decision. Examples can include risk-management documentation, pharmacovigilance activities, educational materials where additional risk-minimisation measures are imposed, and regulatory databases or records.

The precise implementation requirements must always be derived from the decision and its annexes rather than inferred from the existence of a PRAC recommendation.

15. Implementing the Outcome for Nationally Authorised Medicines

The implementation model is different for nationally authorised medicines.

The Union-level conclusion must be reflected in the relevant national marketing authorisations through the applicable procedure. Member States therefore remain important actors even though the scientific assessment has taken place at Union level.

For an MAH with products in several Member States, this creates a second layer of implementation control.

The company needs to establish:

• which national authorisations are within scope;
• which Member States are affected;
• what regulatory action is required in each authorisation;
• what product-information text has been agreed;
• what national procedural steps are required; and
• how completion of implementation will be documented.

A single scientific conclusion can therefore result in multiple national regulatory implementation records.

This is one reason why a referral concerning nationally authorised medicines can be operationally complex even when the scientific assessment itself is centralised.

16. The MAH's First Task After Receiving the PRAC Recommendation

The MAH should not wait for the final legal decision before understanding the likely operational consequences of the PRAC recommendation.

However, it must also avoid treating the PRAC recommendation as though it were already the final legally binding instruction.

A useful internal sequence is:

PRAC recommendation received
          ↓
Scientific and regulatory gap analysis
          ↓
Identify CHMP/CMDh pathway
          ↓
Assess possible final outcomes
          ↓
Prepare implementation scenarios
          ↓
Monitor subsequent committee decision
          ↓
Receive final regulatory instrument
          ↓
Implement the legally operative outcome

The distinction between planning and implementation is important.

An MAH can prepare implementation scenarios before the final decision. It should not represent an anticipated outcome as though it were already legally effective.

17. What the QPPV Should Do at This Stage

The QPPV's role is not to take over the regulatory function of the company. The QPPV should ensure that the pharmacovigilance implications of the emerging regulatory outcome are understood and appropriately governed.

The QPPV should consider whether the recommendation or subsequent opinion affects:

• the safety profile of the product;
• the reference safety information used in pharmacovigilance activities;
• signal-management activities;
• individual case processing or follow-up;
• aggregate reporting;
• risk-management plans;
• additional pharmacovigilance activities;
• additional risk-minimisation measures; and
• ongoing safety monitoring.

The QPPV should also establish whether the company's existing pharmacovigilance system remains aligned with the regulatory conclusion.

For example, if a referral changes the recognised risk profile, the change may affect signal-management assumptions, case follow-up, medical review, aggregate reporting and the way future cases are evaluated.

The referral therefore does not end when the regulatory decision is published. Its consequences enter the routine pharmacovigilance system.

18. The Difference Between a Recommendation and an Implementation Instruction

The distinction can be illustrated with a hypothetical example.

Suppose PRAC recommends that a serious adverse reaction be added to the product information and that an additional risk-minimisation measure be introduced.

At this stage the MAH knows what PRAC considers scientifically and regulatorily appropriate.

If the procedure then requires CHMP to adopt an opinion, the company must assess the CHMP outcome separately. If the European Commission subsequently adopts a decision, that decision establishes the legally operative Union requirement for a CAP.

The sequence is therefore:

PRAC recommendation

“What PRAC recommends.”

CHMP opinion

“What CHMP concludes within its legal remit.”

Commission decision

“What becomes legally binding through the applicable Union act.”

Implementation

“How the MAH and, where applicable, Member States put the legal outcome into effect.”

These are related but different regulatory events.

19. What If the MAH Disagrees?

Disagreement can occur at several levels.

The MAH may disagree with:

• the scientific interpretation of the evidence;
• the characterisation of the risk;
• the proposed regulatory measure;
• the wording of product-information changes; or
• the proportionality of the recommended action.

The appropriate response depends on the stage of the procedure.

During the PRAC assessment, the MAH can respond to questions and provide scientific evidence within the applicable procedural framework.

After a CHMP opinion, the MAH may have a right to request re-examination where the applicable legislation provides for it. The request must follow the statutory procedural requirements and deadlines.

After a final legally operative decision, the available routes depend on the legal nature of the act and the applicable EU legal framework. The company should not assume that an ordinary regulatory response mechanism remains available simply because it disagrees with the outcome.

This makes procedural awareness as important as scientific disagreement.

20. Re-examination Is Not a Second Referral

A re-examination should not be understood as starting the entire referral again from the beginning.

Its purpose is to allow the committee to reconsider its opinion on the basis of the grounds submitted under the applicable legal procedure.

For the MAH, a strong re-examination request therefore needs to identify the specific aspects of the opinion that are challenged and the scientific or procedural basis for the challenge.

A general statement that the company disagrees with the outcome is not equivalent to a structured re-examination case.

The company should distinguish:

1. factual errors;
2. scientific interpretation with which it disagrees;
3. methodological concerns;
4. evidence that was not adequately considered;
5. new or newly interpreted evidence where procedurally relevant; and
6. concerns about the proportionality or feasibility of the proposed regulatory action.

The exact admissibility and scope of arguments depend on the applicable procedure and should be assessed against the current legal framework.

21. Reading the Final Regulatory Outcome

A completed referral should be reconstructed from its documents rather than from a single summary webpage.

A useful hierarchy is:

The precise document set varies by procedure.

A regulatory professional should therefore resist the temptation to treat an EMA webpage summary as the entire regulatory record.

22. Common Misconceptions

“PRAC decided to change the product information.”

More precisely, PRAC recommended regulatory action. The subsequent legal pathway determines how that recommendation becomes operative.

“CHMP simply approves whatever PRAC recommends.”

Not necessarily. CHMP has its own scientific and regulatory remit and can differ from PRAC, with the scientific grounds for a difference explained where required.

“CMDh is the equivalent of CHMP for all national medicines.”

CMDh has a specific coordination role within the nationally authorised medicines framework. Its legal function should be described according to the applicable procedure.

“The European Commission is just an administrative rubber stamp.”

The Commission's decision-making role is a legally defined function. The Commission decision is the legally operative Union act where the legislation provides for one.

“Once PRAC publishes its recommendation, the MAH can implement it immediately as a final legal requirement.”

The company can prepare for implementation, but the legally operative requirement must be identified from the applicable final regulatory instrument.

“A referral is finished when the Commission decision is published.”

The regulatory decision may be the end of the decision-making phase, but implementation, pharmacovigilance follow-up and risk-management activities can continue for years.

23. Inspection Considerations

A referral can become an important inspection topic because it connects the pharmacovigilance system to formal regulatory action.

Inspectors may be interested in whether the MAH can demonstrate:

• how the company assessed the referral outcome;
• how responsibilities were allocated;
• how the final regulatory requirements were translated into operational actions;
• whether product-information changes were implemented correctly;
• whether risk-management measures were updated where required;
• whether relevant pharmacovigilance procedures were updated;
• whether safety databases and case-processing practices reflected the new safety information;
• whether required communications and educational materials were controlled; and
• whether completion of implementation was documented.

A particularly important control is the distinction between anticipated regulatory action and final regulatory obligation.

An inspection record should make it possible to determine when the company knew that an action was recommended, when it became legally required, when implementation began and when implementation was completed.

The exact dates and requirements depend on the individual procedure and should be derived from the formal regulatory documents.

24. A Practical QPPV Review After the Final Decision

Once the legally operative outcome is available, the QPPV can use a structured review.

Product

Which products and authorisations are affected?

Risk

What safety conclusion has been reached?

Product information

What changes have been legally adopted?

Risk management

Are changes to the RMP or risk-minimisation measures required?

Pharmacovigilance system

Do procedures, case assessment, signal management or aggregate reporting need adjustment?

Monitoring

What ongoing safety questions remain?

Governance

Who owns each implementation activity and how is completion demonstrated?

Follow-up

What further regulatory or pharmacovigilance action remains open?

This converts the referral from a regulatory event into a controlled lifecycle activity.

25. The Referral as a Lifecycle Event

The most useful way to understand the post-PRAC period is not as a sequence of disconnected committee meetings.

It is a transition:

Safety concern
      ↓
PRAC assessment
      ↓
PRAC recommendation
      ↓
CHMP / CMDh consideration
      ↓
Commission decision where applicable
      ↓
Authorisation implementation
      ↓
Product-information / RMP changes
      ↓
Risk-minimisation implementation
      ↓
Ongoing pharmacovigilance
      ↓
Further regulatory action if evidence changes

The final stage is deliberately open-ended.

A regulatory conclusion does not freeze the scientific knowledge of the medicine. New evidence can later lead to further signal evaluation, variation, referral or other regulatory action.

The EU medicines regulatory system therefore remains a lifecycle system even after a referral has concluded.

26. Key Takeaways

1. A PRAC recommendation is an important scientific and regulatory milestone, but it is not automatically the final legal outcome.
2. The post-PRAC pathway depends on the legal basis and the authorisation status of the products concerned.
3. Article 20 pharmacovigilance procedures for centrally authorised medicines proceed from PRAC to CHMP and then, where applicable, to a European Commission decision.
4. Article 31 pharmacovigilance referrals can follow different pathways depending on whether centrally authorised medicines are included.
5. CMDh has a coordination role for applicable nationally authorised medicine procedures; it is not simply a national equivalent of CHMP.
6. The European Commission adopts the legally binding Union decision where the legislation provides for one.
7. A CHMP opinion and a Commission decision are different regulatory instruments.
8. Where permitted, re-examination provides a formal mechanism for challenging a CHMP opinion before it becomes final under the applicable procedure.
9. Product-information changes must be implemented from the legally operative outcome, not inferred solely from a preliminary recommendation.
10. For nationally authorised medicines, implementation may require coordinated action across multiple Member States.
11. The QPPV should assess the effect of the outcome on the pharmacovigilance system, risk-management activities and ongoing safety monitoring.
12. A referral does not end from a pharmacovigilance perspective when the final decision is adopted; implementation and subsequent monitoring remain part of the product lifecycle.

The next article examines the organisation on the other side of the procedure: what happens to the marketing authorisation holder during an EMA referral, how the company should organise its response, and how regulatory, pharmacovigilance, medical and quality functions interact.

27. Final Regulatory Reading Framework

A completed referral is easiest to understand when four questions are kept separate:

1. What did PRAC conclude about the safety issue?
2. What did CHMP or CMDh conclude within the applicable legal procedure?
3. What is the legally operative regulatory outcome?
4. What must the MAH and, where applicable, Member States implement?

These questions often have answers in different documents.

For a CAP, the final Commission decision is particularly important when the legislation requires a Commission decision. For NAPs, the implementation pathway must be read against the applicable national authorisation framework and the Union procedure.

The regulatory professional should therefore reconstruct the chain rather than rely on shorthand such as “EMA changed the label”.

A more precise statement identifies the scientific assessment, committee conclusion, legal act and implementation separately.

28. A Worked Example

Consider a hypothetical Article 31 pharmacovigilance referral concerning an active substance marketed through both centrally and nationally authorised products.

PRAC concludes that a serious risk is sufficiently supported by the evidence and recommends changes to product information and additional risk-minimisation measures.

Because centrally authorised products are included, the recommendation proceeds to CHMP. CHMP agrees with the recommendation and adopts its opinion.

The European Commission subsequently adopts the applicable legally binding decision.

The CAPs are then updated through the centralised regulatory framework. The NAPs require implementation through the applicable national procedures.

The company now has several distinct obligations:

• implement the final product-information wording;
• update risk-management documentation where required;
• implement any additional risk-minimisation measures;
• update relevant pharmacovigilance processes;
• ensure appropriate communication and training where required; and
• maintain evidence that implementation was completed.

The important lesson is that one scientific conclusion can produce different implementation pathways without producing different scientific conclusions.

29. Why the Distinction Matters for Regulatory Strategy

For an MAH, the distinction between recommendation, opinion and decision affects both timing and risk management.

Before the final legal outcome, the company may reasonably prepare implementation scenarios. It should not, however, treat an anticipated outcome as legally effective.

Once the final act is adopted, the company must shift from scenario planning to controlled implementation.

This also affects internal escalation. Senior management may need to understand the likely commercial and operational consequences before the final decision, while regulatory and pharmacovigilance functions must maintain a strict distinction between forecasting and legal obligation.

A mature regulatory organisation can therefore prepare early without confusing preparation with premature implementation.

30. What the QPPV Should Retain as Evidence

From a pharmacovigilance-system perspective, the QPPV should be able to reconstruct the company's response to the referral.

Relevant evidence may include:

• the original referral notification;
• regulatory correspondence;
• safety assessments;
• questions and answers exchanged during the procedure;
• the company's submissions;
• PRAC and subsequent committee documents;
• the final regulatory decision where applicable;
• updated product information;
• RMP or risk-minimisation updates;
• implementation records; and
• evidence of follow-up activities.

The purpose is not to create unnecessary duplicate records. It is to preserve a coherent and auditable connection between the regulatory event and the pharmacovigilance system.

The records should make it possible to answer a straightforward inspection question:

How did the company translate the regulatory outcome into its pharmacovigilance system?

31. The Most Important Practical Distinction

The entire post-PRAC process can be reduced to one regulatory discipline:

Never confuse what has been recommended with what has become legally effective.

PRAC can recommend.

CHMP can adopt an opinion.

CMDh can adopt the applicable coordinated position.

The European Commission can adopt a legally binding Union decision where required.

The MAH and Member States then implement the applicable legal outcome according to the authorisation framework.

That sequence is more precise than saying that “EMA decided to change the medicine”.

For anyone working in pharmacovigilance or regulatory affairs, this precision is not semantic. It determines what the company is required to do, when it is required to do it and which regulatory document establishes the obligation.

References

1. European Parliament and Council. Regulation (EC) No 726/2004, as amended. EUR-Lex. Legal framework for centrally authorised medicinal products, EMA and the centralised procedure.
2. European Parliament and Council. Directive 2001/83/EC, as amended. EUR-Lex. Legal framework for medicinal products for human use and the referral procedures applicable to nationally authorised medicines.
3. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current EMA procedure-specific guidance concerning PRAC, CHMP, the European Commission and implementation.
4. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. Current EMA guidance concerning PRAC, CHMP, CMDh, re-examination and Commission decision-making.
5. European Medicines Agency. Questions and answers: Urgent Union procedures (Article 107i). Current guidance for the specific urgent Union pharmacovigilance pathway.
6. European Medicines Agency. Referral procedures for human medicines. Current overview of referral mechanisms and procedural pathways.
7. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Current information on CHMP's scientific responsibilities.
8. European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Current information on PRAC's responsibilities.
9. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current information on CMDh's role in nationally authorised medicines.
10. European Commission. Pharmaceutical legislation and centralised marketing authorisation framework. Current information concerning the Commission's role in EU medicines regulation.
11. European Medicines Agency. Good Pharmacovigilance Practices (GVP), including Module V on Risk Management Systems and Module IX on Signal Management. Current guidance relevant to post-referral pharmacovigilance implementation.

Regulatory Note

This article is an educational explanation of the regulatory pathway following a PRAC recommendation. It is not legal advice and does not replace the applicable EU legislation, current EMA procedural guidance, CMDh guidance, national competent-authority requirements or the documents governing an individual referral.

The exact sequence, legal effect, deadlines, right of re-examination, implementation mechanism and addressee of the final regulatory act depend on the legal basis and products included in the individual procedure.

Particular care should be taken not to treat a PRAC recommendation, CHMP opinion, CMDh position and European Commission decision as interchangeable documents. They have different functions within the EU regulatory system.

The article describes the general architecture. For a live referral, the formal referral notification, applicable legislation, current procedural timetable, adopted committee documents, final Commission decision where applicable, and national implementation requirements should be reviewed directly.

The regulatory requirements applicable to a product may change after a referral through subsequent variations, additional pharmacovigilance measures, risk-management updates or further regulatory procedures. Completion of a referral therefore does not remove the MAH's continuing pharmacovigilance and regulatory obligations.